Zero to Breakthrough | Healthcare Summit 2018

In the biotechnology business change happens fast. Decades of burning cash can be reversed by a single important product. Pharmaceutical research is famously expensive and wasteful. Yet we are in a time when more and more real advances are being developed to help patients. Here, we take stock. Doug Ingram, President & Chief Executive Officer, Sarepta Therapeutics, Jeff Jonas, M.D., Chief Executive Officer, Sage Therapeutics, Jeffrey Leiden, Chairman, President & Chief Executive Officer, Vertex Pharmaceuticals, and John Maraganore, Chief Executive Officer, Alnylam Pharmaceuticals speak with Matthew Herper, Senior Editor, Pharma & Healthcare, Forbes Media.

Subscribe to FORBES: https://www.youtube.com/c/ForbesLive?sub_confirmation=1

Stay Connected
Forbes on Facebook: http://fb.com/forbes
Forbes Video on Twitter: http://www.twitter.com/forbesvideo
Forbes Video on Instagram: http://instagram.com/forbesvideo
More From Forbes: http://forbes.com

Forbes covers the intersection of entrepreneurship, wealth, technology, business and lifestyle with a focus on people and success.

Видео Zero to Breakthrough | Healthcare Summit 2018 канала Forbes Digital Assets